Spine Center, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Biomark Med. 2024;18(17-18):739-747. doi: 10.1080/17520363.2024.2389038. Epub 2024 Sep 4.
This study aimed to evaluate the predictive value of IL-6 for stroke recurrence in acute ischemic stroke. Patients who were admitted within 48 h of onset were included. At 3-month, stroke recurrence was assessed. IL-6 levels were measured in serum samples taken upon admission. Out of the 305 patients, 47 (15.4%) experienced a stroke recurrence. The risk of stroke recurrence increased by 8% (OR: 1.08; 95% CI: 1.04-1.11; < 0.001) for every 1 pg/ml increase in IL-6 serum level, both in unadjusted and adjusted analyses (6%; OR: 1.06; 95% CI: 1.02-1.10; = 0.001). The study supports the usefulness of IL-6 as a predictive biomarker for stroke recurrence after acute ischemic stroke.
这项研究旨在评估 IL-6 对急性缺血性脑卒中患者卒中复发的预测价值。纳入发病后 48 小时内入院的患者。在 3 个月时评估卒中复发情况。在入院时采集的血清样本中测量 IL-6 水平。在 305 名患者中,47 名(15.4%)发生卒中复发。在未调整和调整分析中,IL-6 血清水平每增加 1pg/ml,卒中复发的风险增加 8%(OR:1.08;95%CI:1.04-1.11;<0.001)(6%;OR:1.06;95%CI:1.02-1.10;=0.001)。该研究支持 IL-6 作为急性缺血性脑卒中后卒中复发的预测生物标志物的有用性。